Physician profile
Michael S Henner
NPI 1396704649
$1,568.53
in general payments reported to CMS, 2019-2025
19 companies · $523 in 2025
The $523 reported for 2025 was more than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $32.81 · 2020: $28.40 · 2021: $53.70 · 2022: $76.69 · 2023: $183 · 2024: $671 · 2025: $523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,376.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $288.29 | 2020-2025 | |
| Sun Pharmaceutical Industries INC. | $264.60 | 2023-2025 | Odomzo, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $231.51 | 2024-2025 | Sotyktu |
| Genzyme Corporation | $187.23 | 2022-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $127.01 | 2019-2025 | Jublia, Cabtreo, Arazlo |
| Novartis Pharmaceuticals Corporation | $105.92 | 2025 | |
| Incyte Corporation | $56.09 | 2024-2025 | Opzelura |
| Janssen Biotech, INC. | $44.83 | 2022-2025 | Tremfya |
| Ucb, INC. | $37.95 | 2024-2025 | Bimzelx |
| Smith+Nephew, INC. | $31.90 | 2024 | Renasys Go V2 Home |
| Kerecis Limited | $31.85 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Regeneron Healthcare Solutions, INC. | $25.68 | 2024 | Dupixent |
| Journey Medical Corporation | $23.81 | 2025 | |
| Galderma Laboratories, L.P. | $21.67 | 2024 | |
| Botanix Sb INC | $19.68 | 2025 | Sofdra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.55 | 2024 | Cyltezo |
| Arcutis Biotherapeutics, INC. | $18.47 | 2024 | Zoryve |
| Amgen INC. | $16.98 | 2025 | Otezla |
| Organogenesis INC. | $15.51 | 2023 | Puraply |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Henner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.